PubRank

B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 27048211)

Published in Blood on April 05, 2016

Authors

Gero Knittel1, Paul Liedgens1, Darya Korovkina1, Jens M Seeger2, Yussor Al-Baldawi3, Mona Al-Maarri4, Christian Fritz1, Katerina Vlantis5, Svetlana Bezhanova6, Andreas H Scheel7, Olaf-Oliver Wolz8, Maurice Reimann9, Peter Möller10, Cristina López11, Matthias Schlesner12, Philipp Lohneis13, Alexander N R Weber8, Lorenz Trümper14, German International Cancer Genome Consortium Molecular Mechanisms in Malignant Lymphoma by Sequencing Project Consortium, Louis M Staudt15, Monika Ortmann7, Manolis Pasparakis5, Reiner Siebert11, Clemens A Schmitt16, Andreas R Klatt17, F Thomas Wunderlich4, Stephan C Schäfer7, Thorsten Persigehl3, Manuel Montesinos-Rongen18, Margarete Odenthal19, Reinhard Büttner20, Lukas P Frenzel21, Hamid Kashkar22, H Christian Reinhardt23

Author Affiliations

1: Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany;
2: Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Institute for Microbiology and Hygiene, and.
3: Department of Radiology, Medical Faculty, University Hospital of Cologne, Cologne, Germany;
4: Max Planck Institute for Metabolism Research, Cologne, Germany;
5: Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany;
6: Institute of Pathology, University Hospital of Cologne, Cologne, Germany; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia;
7: Institute of Pathology, University Hospital of Cologne, Cologne, Germany;
8: Interfaculty Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany;
9: Department of Hematology/Oncology, Charité-University Medical Center, Berlin, Germany;
10: Institute of Pathology, Medical Faculty of Ulm University, Ulm, Germany;
11: Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany;
12: Department of Theoretical Bioinformatics, German Cancer Research Center, Heidelberg, Germany;
13: Department of Pathology, Charité-University Medical Center, Berlin, Germany;
14: Department of Hematology and Oncology, Georg-August University, Goettingen, Germany;
15: Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
16: Department of Hematology/Oncology, Charité-University Medical Center, Berlin, Germany; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany;
17: Institute for Clinical Chemistry.
18: Institute of Neuropathology, and.
19: Institute of Pathology, University Hospital of Cologne, Cologne, Germany; Center of Integrated Oncology, University Hospital of Cologne, Cologne, Germany; and.
20: Institute of Pathology, University Hospital of Cologne, Cologne, Germany; Center of Integrated Oncology, University Hospital of Cologne, Cologne, Germany; and Center of Molecular Medicine, University of Cologne, Cologne, Germany.
21: Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Center of Integrated Oncology, University Hospital of Cologne, Cologne, Germany; and.
22: Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Institute for Microbiology and Hygiene, and Center of Molecular Medicine, University of Cologne, Cologne, Germany.
23: Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Center of Integrated Oncology, University Hospital of Cologne, Cologne, Germany; and Center of Molecular Medicine, University of Cologne, Cologne, Germany.

Articles citing this ↘

Transgenic mouse model of IgM(+) lymphoproliferative disease mimicking Waldenström macroglobulinemia. Blood Cancer J (2016) 0.75

B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study. EBioMedicine (2017) 0.75

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun (2017) 0.75

Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study. J Clin Pathol (2017) 0.75

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM. J Exp Med (2017) 0.75

Articles cited by this ↗

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32

Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74

Pattern recognition receptors and inflammation. Cell (2010) 21.05

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37

Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43

Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90

B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res (1997) 5.43

IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2008) 5.42

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A (2002) 4.86

Direct activation of protein kinases by unanchored polyubiquitin chains. Nature (2009) 4.65

Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature (2010) 4.61

Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell (2004) 4.31

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med (2012) 4.26

AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell (2008) 4.13

Distinct molecular mechanism for initiating TRAF6 signalling. Nature (2002) 3.82

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50

Regulation of AID expression in the immune response. J Exp Med (2007) 2.35

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07

Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol (2006) 2.06

Mutations driving CLL and their evolution in progression and relapse. Nature (2015) 2.06

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood (2009) 2.04

B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med (2007) 1.89

Malignant pirates of the immune system. Nat Immunol (2011) 1.87

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood (2002) 1.86

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood (2013) 1.79

Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol (2004) 1.76

bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells. J Exp Med (2000) 1.76

Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70

BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.62

Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med (2015) 1.51

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood (2011) 1.51

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood (2013) 1.38

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med (2013) 1.35

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia (2013) 1.30

DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nat Genet (2015) 1.26

Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. Haematologica (2008) 1.15

Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol (2013) 1.09

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2015) 1.07

Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med (2013) 1.05

Dual-reactive B cells are autoreactive and highly enriched in the plasmablast and memory B cell subsets of autoimmune mice. J Exp Med (2012) 0.96

Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance. J Exp Med (2014) 0.94

Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol (2015) 0.89

Aggressive B-cell lymphomas: how many categories do we need? Mod Pathol (2012) 0.86

Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells. J Biol Chem (2013) 0.84

L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. PLoS One (2013) 0.83

CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol (2013) 0.83

B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. Anticancer Res (2005) 0.82

Waldenström macroglobulinemia: What a hematologist needs to know. Blood Rev (2015) 0.79

A practical approach to the understanding and diagnosis of lymphoma: an assessment of the WHO classification based on immunoarchitecture and immuno-ontogenic principles. Pathology (2009) 0.78

Mechanisms of intracerebral lymphoma growth delineated in a syngeneic mouse model of central nervous system lymphoma. J Neuropathol Exp Neurol (2013) 0.76

Articles by these authors ⇆

Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood (2014) 0.95